DealForma (@DealForma) header
DealForma (@DealForma) profile picture

The deal and funding database built for biopharma. Curated deal comps, company profiles, pipelines, dedicated analyst support so you do better research faster

San Mateo, CA
Joined January 2017
Eli Lilly was the most active large-cap biopharma buyer across 2025–2026 YTD, leading both deal count and total announced value. Find additional biopharma deal data and charts on DealForma.
1
31
Biopharma M&A continued to focus on later-stage and commercially proven assets in 2026 YTD. Find additional biopharma deal data and charts on DealForma.
1
19
Biopharma M&A slowed in Q3 2026 after a very strong second quarter, but year-to-date activity remains ahead of 2025 on total value. Find additional biopharma deal data and charts on DealForma.
1
31
Biopharma reverse merger and de-SPAC activity picked up sharply in 2026. Find additional biopharma deal data and charts on DealForma.
1
1
44
Biopharma PIPE financing remained active in Q3 2026, even as follow-on activity slowed. Find additional biopharma deal data and charts on DealForma.
1
1
75
U.S. biopharma IPO activity remained strong in Q3 2026, extending the rebound seen earlier in the year. Find additional biopharma deal data and charts on DealForma.
1
29
Early-stage biopharma funding in 2026 YTD remained concentrated in biologics and cancer, although overall investment is running below 2025 levels in several major categories. Find additional biopharma deal data and charts on DealForma.
1
1
60
Biopharma R&D partnerships kept their pace in Q3 2026, but the deals were worth far less in total. The number of deals rose slightly, and the typical upfront payment grew. However, fewer and smaller deals drove the drop in total value. Read our research na2.hubs.ly/H08NSnt0
2
38
Biopharma venture rounds grew larger across most development stages in 2026 YTD. Find additional biopharma deal data and charts on DealForma.
26
Later-stage biopharma venture financing continued to attract more capital than first-round funding in 2026 YTD. Find additional biopharma deal data and charts on DealForma.
1
47
UK and Swiss biopharma led European venture fundraising through Q3 2026. Find additional biopharma deal data and charts on DealForma.
1
1
74
Biopharma venture activity remained concentrated in the largest U.S. life sciences hubs through Q3 2026. Find additional biopharma deal data and charts on DealForma.
1
1
47
AI/ML has become one of the largest destinations for biopharma venture capital in 2025–2026 YTD. Find additional biopharma deal data and charts on DealForma.
2
1
3
282
Biopharma venture activity slowed across financing stages in Q3 2026. Find additional biopharma deal data and charts on DealForma.
1
64
Biopharma venture investment pulled back in Q3 2026 after a stronger first half. Find additional biopharma deal data and charts on DealForma.
1
46
Discovery-stage licensing in 2025–2026 YTD has been concentrated around antibodies, small molecules, and AI/ML platforms. Find additional biopharma deal data and charts on DealForma.
1
2
79
AI-based target and drug discovery licensing continued to climb in 2026. Find additional biopharma deal data and charts on DealForma.
1
2
84
Large-cap biopharma continued to concentrate in-licensing activity at the earliest stages in 2026. Find additional biopharma deal data and charts on DealForma.
2
4
203
Discovery-stage licensing in 2025–2026 YTD has been dominated by antibodies, small molecules, and AI/ML platforms. Find additional biopharma deal data and charts on DealForma.
1
44
AI-based target and drug discovery licensing accelerated sharply in 2026. Find additional biopharma deal data and charts on DealForma.
2
59